User login
Identifying and stopping a likely mass shooter: A case study
AUSTIN, TEX. – While the media relentlessly reports on every mass shooting that occurs, the public hears less often about the shootings that never happened – because people were paying attention and taking action, according to James L. Knoll, IV, MD, director of forensic psychiatry at the State University of New York, Syracuse.
“We’ve learned a lot about risk factors [for mass shootings], we’ve learned a lot about associations and correlations, and it’s gotten us so far,” Dr. Knoll told attendees at the annual meeting of the American Academy of Psychiatry and the Law. “I want to invite you to look at this from the angle of those shootings that were able to be prevented or disrupted.” (Dr. Knoll said he used the term “disrupted” because it’s impossible to ever know for certain that a shooting was thwarted.)
It is difficult to track mass homicides that would have occurred but were disrupted, but one study Dr. Knoll cited combed through news reports and identified 57 interrupted mass homicides (Aggress Viol Behav. 2016 Sep-Oct;30:88-93). Most of those (77%) had been interrupted by family and friends or the general public reporting suspicious behavior.
It was while Dr. Knoll was leading the threat assessment subcommittee of the Syracuse School Safety Task Force that a potential school shooting threat arose.
A 22-year-old Chinese international student named Xiaofeng “Lincoln” Zhan walked into AJ’s Archery/The Gun Shop on March 12, asking to buy an AR-15. The AR-15 is the semiautomatic weapon of choice for most mass shooters.
Mr. Zhan should have been barred from purchasing a gun because he was an international student on a temporary visa. Under U.S. code, it is “unlawful for any person to sell or otherwise dispose of any firearm or ammunition to any person knowing or having reasonable cause to believe that such person” is an alien who is “illegally or unlawfully in the United States” or “ has been admitted to the United States under a nonimmigrant visa.”
But the second provision was subject to certain exceptions, the first of which was that the person had been “admitted to the United States for lawful hunting or supporting purposes“ or was “in possession of a hunting license or permit lawfully issued in the United States.”
Mr. Zhan had a hunting license. He had taken a hunter safety course on March 11, the day before he entered the gun shop, and then bought a hunting license.
But the gun shop owner was not so easily persuaded. Mr. Zhan asked about “high-capacity shotguns” and said he belonged to a shooting club, yet he did not appear familiar with firearms. The gun shop owner was also skeptical because it didn’t make sense to use a high-capacity shotgun for hunting, and Mr. Zhan had just gotten his hunting license and didn’t know how to use the gun. Further, Mr. Zhan claimed that Syracuse University offered a class on how to use the gun – but the gun store owner knew that the university did not offer such a class.
The gun shop owner’s first thought was not that Mr. Zhan was a potential mass shooter but that he was a “secret shopper,” which Dr. Knoll defined as an undercover law enforcement officer who attempts to buy guns in a manner that should arouse suspicion in the store owner.
Ultimately, Zhan’s behavior was concerning and he made the owner feel uncomfortable. The owner captured Mr. Zhan’s information on U.S. ATF form 4473 and recorded his license plate. Then the gun shop owner contacted the Madison County Sheriff’s Office with the information.
The police opened an investigation that established that Mr. Zhan was a student enrolled at Syracuse University, which was on spring break at the time. The Syracuse Police Department arranged a joint meeting between the Onondaga County district attorney, Syracuse University Department of Public Safety, Onondaga County Sheriff’s Office, and the FBI to present their findings, including the fact that local high schools were planning walk-outs that might be potential targets.
Further investigation revealed that Mr. Zhan had been a student at Northeastern University in Boston in 2015, where he had asked a teacher how to get guns. The teacher emailed his supervisor, but the university police found no concerns.
Meanwhile, the police obtained a subpoena to get Mr. Zhan’s mental health records from Syracuse University. Mr. Zhan had sought psychiatric care at two facilities, Northeastern University in 2015 and Syracuse University in 2018. His mental health records revealed alcohol abuse, depression, suicidal thinking, anger problems, feelings of isolation and withdrawal, and his feeling that he might lose control or act violently, said Dr. Knoll, who is also professor of psychiatry at the university.
On March 13, the day after he had attempted to buy the gun, Syracuse University’s mental health services were contacted and briefed on Mr. Zhan. They filled out the paperwork for New York’s SAFE Act, which prevents people from buying a gun if a mental health professional makes the reasonable judgment that the individual might harm themselves or someone else.
The police investigation continued and found that Mr. Zhan had previously tried to buy an AR-15 at a Dick’s Sporting Goods store. He was denied because the SAFE Act prevents their sale.
Mr. Zhan, meanwhile, had gone to Mexico for the break and was due to return March 19. While he was away, an alarm allegedly went off in his apartment on March 16, leading the landlord to check on the apartment since he remembered previous police inquiries. He knocked on the door but there was no answer, so the landlord entered to do a safety check. He found ammunition and other concerning supplies.
The same day the landlord was checking Mr. Zhan’s apartment, students traveling with him in Mexico emailed Syracuse University about concerning behavior they observed in him. This behavior included signs of severe depression, verbalizing extremely negative thoughts, discussing suicide, drinking heavily, and making cuts to his forearms with the knife he possessed.
They also shared screenshots of messages they had seen him post in a social media group about feeling compelled to buy a gun and bulletproof vest and practice shooting.
Three days later, the police obtained a search warrant for Mr. Zhan’s apartment and vehicle. They found in his apartment high-powered optics, scopes, ammunition, targets from shooting ranges, receipts from shooting ranges, and similar equipment.
Ultimately, authorities revoked Mr. Zhan’s visa, enabling them to detain him at the airport when he returned from Mexico and deport him back to China.
After Mr. Zhan had returned to China, further investigation uncovered a series of texts between Mr. Zhan and his girlfriend in which he openly talks about wanting to shoot people.
“So, what went right here instead of what went wrong?” Dr. Knoll rhetorically asked. A lot of things: leakage of Mr. Zhan’s plans; fellow students seeing and reporting his electronic messages and concerning behaviors; the gun store owner’s skepticism and contact with the police; the landlord’s check on Mr. Zhan’s apartment; and the cooperation among local police, school authorities, and the school’s mental health services.
“There was also good communication among the threat assessment teams and law enforcement and the collaboration across disciplines,” Dr. Knoll said. Mass shootings have now “taken on more of a sociocultural phenomenon,” and “sociocultural problems require sociocultural solutions. I like these laws focusing on behaviors, not psychiatric diagnoses.”
He then reviewed potential interventions that might help identify or interfere with a planned incident or intent to commit one, including increased attention paid to suspicious behavior, third-party reporting of a potential shooter’s intent, and suicide prevention programs.
Dr. Knoll shared recent FBI research on 63 active shooters between 2000 and 2013 showing that the majority (77%) had been planning their attack for at least 1 week. Further, 46% have been preparing for 1 week before. The majority of those likely shooters also obtained their guns legally.
Although a quarter of those in the FBI study had some mental health diagnosis – predominantly depression or anxiety – the agency uncovered no significant correlation between mental illness and becoming a shooter.
The study concluded that,“absent specific evidence, careful consideration should be given to social and contextual factors that might interact with any mental health issue before concluding that an active shooting was ‘caused’ by a mental illness. In short, declarations that all active shooters must simply be mentally ill are misleading and unhelpful.”
Dr. Knoll reported no conflicts of interest.
AUSTIN, TEX. – While the media relentlessly reports on every mass shooting that occurs, the public hears less often about the shootings that never happened – because people were paying attention and taking action, according to James L. Knoll, IV, MD, director of forensic psychiatry at the State University of New York, Syracuse.
“We’ve learned a lot about risk factors [for mass shootings], we’ve learned a lot about associations and correlations, and it’s gotten us so far,” Dr. Knoll told attendees at the annual meeting of the American Academy of Psychiatry and the Law. “I want to invite you to look at this from the angle of those shootings that were able to be prevented or disrupted.” (Dr. Knoll said he used the term “disrupted” because it’s impossible to ever know for certain that a shooting was thwarted.)
It is difficult to track mass homicides that would have occurred but were disrupted, but one study Dr. Knoll cited combed through news reports and identified 57 interrupted mass homicides (Aggress Viol Behav. 2016 Sep-Oct;30:88-93). Most of those (77%) had been interrupted by family and friends or the general public reporting suspicious behavior.
It was while Dr. Knoll was leading the threat assessment subcommittee of the Syracuse School Safety Task Force that a potential school shooting threat arose.
A 22-year-old Chinese international student named Xiaofeng “Lincoln” Zhan walked into AJ’s Archery/The Gun Shop on March 12, asking to buy an AR-15. The AR-15 is the semiautomatic weapon of choice for most mass shooters.
Mr. Zhan should have been barred from purchasing a gun because he was an international student on a temporary visa. Under U.S. code, it is “unlawful for any person to sell or otherwise dispose of any firearm or ammunition to any person knowing or having reasonable cause to believe that such person” is an alien who is “illegally or unlawfully in the United States” or “ has been admitted to the United States under a nonimmigrant visa.”
But the second provision was subject to certain exceptions, the first of which was that the person had been “admitted to the United States for lawful hunting or supporting purposes“ or was “in possession of a hunting license or permit lawfully issued in the United States.”
Mr. Zhan had a hunting license. He had taken a hunter safety course on March 11, the day before he entered the gun shop, and then bought a hunting license.
But the gun shop owner was not so easily persuaded. Mr. Zhan asked about “high-capacity shotguns” and said he belonged to a shooting club, yet he did not appear familiar with firearms. The gun shop owner was also skeptical because it didn’t make sense to use a high-capacity shotgun for hunting, and Mr. Zhan had just gotten his hunting license and didn’t know how to use the gun. Further, Mr. Zhan claimed that Syracuse University offered a class on how to use the gun – but the gun store owner knew that the university did not offer such a class.
The gun shop owner’s first thought was not that Mr. Zhan was a potential mass shooter but that he was a “secret shopper,” which Dr. Knoll defined as an undercover law enforcement officer who attempts to buy guns in a manner that should arouse suspicion in the store owner.
Ultimately, Zhan’s behavior was concerning and he made the owner feel uncomfortable. The owner captured Mr. Zhan’s information on U.S. ATF form 4473 and recorded his license plate. Then the gun shop owner contacted the Madison County Sheriff’s Office with the information.
The police opened an investigation that established that Mr. Zhan was a student enrolled at Syracuse University, which was on spring break at the time. The Syracuse Police Department arranged a joint meeting between the Onondaga County district attorney, Syracuse University Department of Public Safety, Onondaga County Sheriff’s Office, and the FBI to present their findings, including the fact that local high schools were planning walk-outs that might be potential targets.
Further investigation revealed that Mr. Zhan had been a student at Northeastern University in Boston in 2015, where he had asked a teacher how to get guns. The teacher emailed his supervisor, but the university police found no concerns.
Meanwhile, the police obtained a subpoena to get Mr. Zhan’s mental health records from Syracuse University. Mr. Zhan had sought psychiatric care at two facilities, Northeastern University in 2015 and Syracuse University in 2018. His mental health records revealed alcohol abuse, depression, suicidal thinking, anger problems, feelings of isolation and withdrawal, and his feeling that he might lose control or act violently, said Dr. Knoll, who is also professor of psychiatry at the university.
On March 13, the day after he had attempted to buy the gun, Syracuse University’s mental health services were contacted and briefed on Mr. Zhan. They filled out the paperwork for New York’s SAFE Act, which prevents people from buying a gun if a mental health professional makes the reasonable judgment that the individual might harm themselves or someone else.
The police investigation continued and found that Mr. Zhan had previously tried to buy an AR-15 at a Dick’s Sporting Goods store. He was denied because the SAFE Act prevents their sale.
Mr. Zhan, meanwhile, had gone to Mexico for the break and was due to return March 19. While he was away, an alarm allegedly went off in his apartment on March 16, leading the landlord to check on the apartment since he remembered previous police inquiries. He knocked on the door but there was no answer, so the landlord entered to do a safety check. He found ammunition and other concerning supplies.
The same day the landlord was checking Mr. Zhan’s apartment, students traveling with him in Mexico emailed Syracuse University about concerning behavior they observed in him. This behavior included signs of severe depression, verbalizing extremely negative thoughts, discussing suicide, drinking heavily, and making cuts to his forearms with the knife he possessed.
They also shared screenshots of messages they had seen him post in a social media group about feeling compelled to buy a gun and bulletproof vest and practice shooting.
Three days later, the police obtained a search warrant for Mr. Zhan’s apartment and vehicle. They found in his apartment high-powered optics, scopes, ammunition, targets from shooting ranges, receipts from shooting ranges, and similar equipment.
Ultimately, authorities revoked Mr. Zhan’s visa, enabling them to detain him at the airport when he returned from Mexico and deport him back to China.
After Mr. Zhan had returned to China, further investigation uncovered a series of texts between Mr. Zhan and his girlfriend in which he openly talks about wanting to shoot people.
“So, what went right here instead of what went wrong?” Dr. Knoll rhetorically asked. A lot of things: leakage of Mr. Zhan’s plans; fellow students seeing and reporting his electronic messages and concerning behaviors; the gun store owner’s skepticism and contact with the police; the landlord’s check on Mr. Zhan’s apartment; and the cooperation among local police, school authorities, and the school’s mental health services.
“There was also good communication among the threat assessment teams and law enforcement and the collaboration across disciplines,” Dr. Knoll said. Mass shootings have now “taken on more of a sociocultural phenomenon,” and “sociocultural problems require sociocultural solutions. I like these laws focusing on behaviors, not psychiatric diagnoses.”
He then reviewed potential interventions that might help identify or interfere with a planned incident or intent to commit one, including increased attention paid to suspicious behavior, third-party reporting of a potential shooter’s intent, and suicide prevention programs.
Dr. Knoll shared recent FBI research on 63 active shooters between 2000 and 2013 showing that the majority (77%) had been planning their attack for at least 1 week. Further, 46% have been preparing for 1 week before. The majority of those likely shooters also obtained their guns legally.
Although a quarter of those in the FBI study had some mental health diagnosis – predominantly depression or anxiety – the agency uncovered no significant correlation between mental illness and becoming a shooter.
The study concluded that,“absent specific evidence, careful consideration should be given to social and contextual factors that might interact with any mental health issue before concluding that an active shooting was ‘caused’ by a mental illness. In short, declarations that all active shooters must simply be mentally ill are misleading and unhelpful.”
Dr. Knoll reported no conflicts of interest.
AUSTIN, TEX. – While the media relentlessly reports on every mass shooting that occurs, the public hears less often about the shootings that never happened – because people were paying attention and taking action, according to James L. Knoll, IV, MD, director of forensic psychiatry at the State University of New York, Syracuse.
“We’ve learned a lot about risk factors [for mass shootings], we’ve learned a lot about associations and correlations, and it’s gotten us so far,” Dr. Knoll told attendees at the annual meeting of the American Academy of Psychiatry and the Law. “I want to invite you to look at this from the angle of those shootings that were able to be prevented or disrupted.” (Dr. Knoll said he used the term “disrupted” because it’s impossible to ever know for certain that a shooting was thwarted.)
It is difficult to track mass homicides that would have occurred but were disrupted, but one study Dr. Knoll cited combed through news reports and identified 57 interrupted mass homicides (Aggress Viol Behav. 2016 Sep-Oct;30:88-93). Most of those (77%) had been interrupted by family and friends or the general public reporting suspicious behavior.
It was while Dr. Knoll was leading the threat assessment subcommittee of the Syracuse School Safety Task Force that a potential school shooting threat arose.
A 22-year-old Chinese international student named Xiaofeng “Lincoln” Zhan walked into AJ’s Archery/The Gun Shop on March 12, asking to buy an AR-15. The AR-15 is the semiautomatic weapon of choice for most mass shooters.
Mr. Zhan should have been barred from purchasing a gun because he was an international student on a temporary visa. Under U.S. code, it is “unlawful for any person to sell or otherwise dispose of any firearm or ammunition to any person knowing or having reasonable cause to believe that such person” is an alien who is “illegally or unlawfully in the United States” or “ has been admitted to the United States under a nonimmigrant visa.”
But the second provision was subject to certain exceptions, the first of which was that the person had been “admitted to the United States for lawful hunting or supporting purposes“ or was “in possession of a hunting license or permit lawfully issued in the United States.”
Mr. Zhan had a hunting license. He had taken a hunter safety course on March 11, the day before he entered the gun shop, and then bought a hunting license.
But the gun shop owner was not so easily persuaded. Mr. Zhan asked about “high-capacity shotguns” and said he belonged to a shooting club, yet he did not appear familiar with firearms. The gun shop owner was also skeptical because it didn’t make sense to use a high-capacity shotgun for hunting, and Mr. Zhan had just gotten his hunting license and didn’t know how to use the gun. Further, Mr. Zhan claimed that Syracuse University offered a class on how to use the gun – but the gun store owner knew that the university did not offer such a class.
The gun shop owner’s first thought was not that Mr. Zhan was a potential mass shooter but that he was a “secret shopper,” which Dr. Knoll defined as an undercover law enforcement officer who attempts to buy guns in a manner that should arouse suspicion in the store owner.
Ultimately, Zhan’s behavior was concerning and he made the owner feel uncomfortable. The owner captured Mr. Zhan’s information on U.S. ATF form 4473 and recorded his license plate. Then the gun shop owner contacted the Madison County Sheriff’s Office with the information.
The police opened an investigation that established that Mr. Zhan was a student enrolled at Syracuse University, which was on spring break at the time. The Syracuse Police Department arranged a joint meeting between the Onondaga County district attorney, Syracuse University Department of Public Safety, Onondaga County Sheriff’s Office, and the FBI to present their findings, including the fact that local high schools were planning walk-outs that might be potential targets.
Further investigation revealed that Mr. Zhan had been a student at Northeastern University in Boston in 2015, where he had asked a teacher how to get guns. The teacher emailed his supervisor, but the university police found no concerns.
Meanwhile, the police obtained a subpoena to get Mr. Zhan’s mental health records from Syracuse University. Mr. Zhan had sought psychiatric care at two facilities, Northeastern University in 2015 and Syracuse University in 2018. His mental health records revealed alcohol abuse, depression, suicidal thinking, anger problems, feelings of isolation and withdrawal, and his feeling that he might lose control or act violently, said Dr. Knoll, who is also professor of psychiatry at the university.
On March 13, the day after he had attempted to buy the gun, Syracuse University’s mental health services were contacted and briefed on Mr. Zhan. They filled out the paperwork for New York’s SAFE Act, which prevents people from buying a gun if a mental health professional makes the reasonable judgment that the individual might harm themselves or someone else.
The police investigation continued and found that Mr. Zhan had previously tried to buy an AR-15 at a Dick’s Sporting Goods store. He was denied because the SAFE Act prevents their sale.
Mr. Zhan, meanwhile, had gone to Mexico for the break and was due to return March 19. While he was away, an alarm allegedly went off in his apartment on March 16, leading the landlord to check on the apartment since he remembered previous police inquiries. He knocked on the door but there was no answer, so the landlord entered to do a safety check. He found ammunition and other concerning supplies.
The same day the landlord was checking Mr. Zhan’s apartment, students traveling with him in Mexico emailed Syracuse University about concerning behavior they observed in him. This behavior included signs of severe depression, verbalizing extremely negative thoughts, discussing suicide, drinking heavily, and making cuts to his forearms with the knife he possessed.
They also shared screenshots of messages they had seen him post in a social media group about feeling compelled to buy a gun and bulletproof vest and practice shooting.
Three days later, the police obtained a search warrant for Mr. Zhan’s apartment and vehicle. They found in his apartment high-powered optics, scopes, ammunition, targets from shooting ranges, receipts from shooting ranges, and similar equipment.
Ultimately, authorities revoked Mr. Zhan’s visa, enabling them to detain him at the airport when he returned from Mexico and deport him back to China.
After Mr. Zhan had returned to China, further investigation uncovered a series of texts between Mr. Zhan and his girlfriend in which he openly talks about wanting to shoot people.
“So, what went right here instead of what went wrong?” Dr. Knoll rhetorically asked. A lot of things: leakage of Mr. Zhan’s plans; fellow students seeing and reporting his electronic messages and concerning behaviors; the gun store owner’s skepticism and contact with the police; the landlord’s check on Mr. Zhan’s apartment; and the cooperation among local police, school authorities, and the school’s mental health services.
“There was also good communication among the threat assessment teams and law enforcement and the collaboration across disciplines,” Dr. Knoll said. Mass shootings have now “taken on more of a sociocultural phenomenon,” and “sociocultural problems require sociocultural solutions. I like these laws focusing on behaviors, not psychiatric diagnoses.”
He then reviewed potential interventions that might help identify or interfere with a planned incident or intent to commit one, including increased attention paid to suspicious behavior, third-party reporting of a potential shooter’s intent, and suicide prevention programs.
Dr. Knoll shared recent FBI research on 63 active shooters between 2000 and 2013 showing that the majority (77%) had been planning their attack for at least 1 week. Further, 46% have been preparing for 1 week before. The majority of those likely shooters also obtained their guns legally.
Although a quarter of those in the FBI study had some mental health diagnosis – predominantly depression or anxiety – the agency uncovered no significant correlation between mental illness and becoming a shooter.
The study concluded that,“absent specific evidence, careful consideration should be given to social and contextual factors that might interact with any mental health issue before concluding that an active shooting was ‘caused’ by a mental illness. In short, declarations that all active shooters must simply be mentally ill are misleading and unhelpful.”
Dr. Knoll reported no conflicts of interest.
EXPERT ANALYSIS FROM THE AAPL ANNUAL MEETING
Rate of STIs is rising, and many U.S. teens are sexually active
ORLANDO – Consider point-of-care testing and treat potentially infected partners when diagnosing and treating adolescents for STIs, Diane M. Straub, MD, MPH, said at the annual meeting of the American Academy of Pediatrics.
In addition, adolescents are sometimes reluctant to disclose their full sexual history to their health care provider, which can complicate diagnosis and treatment, noted Dr. Straub, professor of pediatrics at the University of South Florida, Tampa. “That sometimes takes a few questions,” but can be achieved by asking the same questions in different ways and emphasizing the clinical importance of testing.
According to the 2017 Youth Risk Behavior Surveillance survey, 40% of adolescents reported ever having sexual intercourse, with 20% of 9th-grade, 36% of 10th-grade, 47% of 11th-grade, and 57% of 12th-grade students reporting they had sexual intercourse. By gender, 41% of adolescent males and 38% of adolescent females reported ever having sexual intercourse; by race, 39% of white, 41% of Hispanic, and 46% of black participants reported any sexual activity. Overall, 10% of adolescents said they had four or more partners, 3% said they had intercourse before age 13 years, 54% used a condom the last time they had intercourse, and 7% said they were raped.
The rate of STIs in the United States is rising. There has been a sharp increase in the number of combined diagnoses of gonorrhea, syphilis, and chlamydia, with an increase from 1.8 million in 2013 to 2.3 million cases in 2017, according to the Centers for Disease Control and Prevention. During that same time period, gonorrhea increased 67% from 333,004 to 555,608 cases, syphilis (primary and secondary) rose 76% from 17,375 to 30,644 cases, and chlamydia increased 22% to 1.7 million cases.
According to a 2013 CDC infographic shown by Dr. Straub, young people in the United States aged 15-24 years old represent 27% of the total sexually active population but account for 50% of new STI cases each year. Persons in this population account for 70% of gonorrhea cases, 63% of chlamydia cases, 49% of human papillomavirus (HPV) cases, 45% of genital herpes cases, and 20% of syphilis cases.
All sexually active females aged 25 years or younger should be screened for chlamydia and gonorrhea, as well as “at-risk” young men who have sex with men (YMSM), Dr. Straub said. All adolescent males and females aged over 13 years should be offered HIV screening, and HIV screening should be discussed “at least once.” And depending on how at risk each subpopulation is, health care providers should be have that conversation and offer screening multiple times.
Women who have sex with women (WSW) are a diverse population and should be treated based on their individual sexual identities, behaviors, and practices. “Most self-identified WSWs report having sex with men, so therefore adolescent WSWs and females with both male and female sex partners might be at increased risk for STIs, such as syphillis, chlamydia, and HPV as well as HIV, so you may want to adjust your screening accordingly,” she said.
Pregnant women, if at risk, should be screened for HIV, syphilis, hepatitis B, gonorrhea, and chlamydia.
YMSM should have annual screenings for syphilis and HIV, screenings for chlamydia and gonorrhea by infection site; also consider herpes simplex virus serology and anal cytology in these patients, Dr. Straub said. They also should be screened for hepatitis B surface antigen, vaccinated for hepatitis A, hepatitis B and, if using drugs, screened* for hepatitis C virus.
Dr. Straub recommended licensed health care professionals who may treat minor patients review their state’s laws on minors and their legal ability to consent to treatment of STIs without the involvement of their parent or guardian, including disclosure of positive results and in the case of HIV care.
In places where index insured are allowed to find out about any services a beneficiary receives on their insurance, “this is a little problematic, because in some states, this is in direct conflict with the explanation of benefits requirement,” she said. “There are certain ways to get around that, but it’s really important for you to know what the statutes are where you’re practicing and where the breaches of confidentiality [are].”
Expedited partner therapy, or treating one or multiple partners of patients with an STI, is recommended for certain patients and infections, such as male partners of female patients with chlamydia and gonorrhea. While this is recommended less for YMSM because of a higher rate of concurrent infection, “if you have a young person who has partners who are unlikely to have access to care and get treated, it’s recommended you give that treatment to your index patient and to then treat their partners,” Dr. Straub said.
A recent and frequently updated resource on STI treatment can be found at the CDC website.
Dr. Straub reported no relevant conflicts of interest.
*This article was updated 1/11/19.
ORLANDO – Consider point-of-care testing and treat potentially infected partners when diagnosing and treating adolescents for STIs, Diane M. Straub, MD, MPH, said at the annual meeting of the American Academy of Pediatrics.
In addition, adolescents are sometimes reluctant to disclose their full sexual history to their health care provider, which can complicate diagnosis and treatment, noted Dr. Straub, professor of pediatrics at the University of South Florida, Tampa. “That sometimes takes a few questions,” but can be achieved by asking the same questions in different ways and emphasizing the clinical importance of testing.
According to the 2017 Youth Risk Behavior Surveillance survey, 40% of adolescents reported ever having sexual intercourse, with 20% of 9th-grade, 36% of 10th-grade, 47% of 11th-grade, and 57% of 12th-grade students reporting they had sexual intercourse. By gender, 41% of adolescent males and 38% of adolescent females reported ever having sexual intercourse; by race, 39% of white, 41% of Hispanic, and 46% of black participants reported any sexual activity. Overall, 10% of adolescents said they had four or more partners, 3% said they had intercourse before age 13 years, 54% used a condom the last time they had intercourse, and 7% said they were raped.
The rate of STIs in the United States is rising. There has been a sharp increase in the number of combined diagnoses of gonorrhea, syphilis, and chlamydia, with an increase from 1.8 million in 2013 to 2.3 million cases in 2017, according to the Centers for Disease Control and Prevention. During that same time period, gonorrhea increased 67% from 333,004 to 555,608 cases, syphilis (primary and secondary) rose 76% from 17,375 to 30,644 cases, and chlamydia increased 22% to 1.7 million cases.
According to a 2013 CDC infographic shown by Dr. Straub, young people in the United States aged 15-24 years old represent 27% of the total sexually active population but account for 50% of new STI cases each year. Persons in this population account for 70% of gonorrhea cases, 63% of chlamydia cases, 49% of human papillomavirus (HPV) cases, 45% of genital herpes cases, and 20% of syphilis cases.
All sexually active females aged 25 years or younger should be screened for chlamydia and gonorrhea, as well as “at-risk” young men who have sex with men (YMSM), Dr. Straub said. All adolescent males and females aged over 13 years should be offered HIV screening, and HIV screening should be discussed “at least once.” And depending on how at risk each subpopulation is, health care providers should be have that conversation and offer screening multiple times.
Women who have sex with women (WSW) are a diverse population and should be treated based on their individual sexual identities, behaviors, and practices. “Most self-identified WSWs report having sex with men, so therefore adolescent WSWs and females with both male and female sex partners might be at increased risk for STIs, such as syphillis, chlamydia, and HPV as well as HIV, so you may want to adjust your screening accordingly,” she said.
Pregnant women, if at risk, should be screened for HIV, syphilis, hepatitis B, gonorrhea, and chlamydia.
YMSM should have annual screenings for syphilis and HIV, screenings for chlamydia and gonorrhea by infection site; also consider herpes simplex virus serology and anal cytology in these patients, Dr. Straub said. They also should be screened for hepatitis B surface antigen, vaccinated for hepatitis A, hepatitis B and, if using drugs, screened* for hepatitis C virus.
Dr. Straub recommended licensed health care professionals who may treat minor patients review their state’s laws on minors and their legal ability to consent to treatment of STIs without the involvement of their parent or guardian, including disclosure of positive results and in the case of HIV care.
In places where index insured are allowed to find out about any services a beneficiary receives on their insurance, “this is a little problematic, because in some states, this is in direct conflict with the explanation of benefits requirement,” she said. “There are certain ways to get around that, but it’s really important for you to know what the statutes are where you’re practicing and where the breaches of confidentiality [are].”
Expedited partner therapy, or treating one or multiple partners of patients with an STI, is recommended for certain patients and infections, such as male partners of female patients with chlamydia and gonorrhea. While this is recommended less for YMSM because of a higher rate of concurrent infection, “if you have a young person who has partners who are unlikely to have access to care and get treated, it’s recommended you give that treatment to your index patient and to then treat their partners,” Dr. Straub said.
A recent and frequently updated resource on STI treatment can be found at the CDC website.
Dr. Straub reported no relevant conflicts of interest.
*This article was updated 1/11/19.
ORLANDO – Consider point-of-care testing and treat potentially infected partners when diagnosing and treating adolescents for STIs, Diane M. Straub, MD, MPH, said at the annual meeting of the American Academy of Pediatrics.
In addition, adolescents are sometimes reluctant to disclose their full sexual history to their health care provider, which can complicate diagnosis and treatment, noted Dr. Straub, professor of pediatrics at the University of South Florida, Tampa. “That sometimes takes a few questions,” but can be achieved by asking the same questions in different ways and emphasizing the clinical importance of testing.
According to the 2017 Youth Risk Behavior Surveillance survey, 40% of adolescents reported ever having sexual intercourse, with 20% of 9th-grade, 36% of 10th-grade, 47% of 11th-grade, and 57% of 12th-grade students reporting they had sexual intercourse. By gender, 41% of adolescent males and 38% of adolescent females reported ever having sexual intercourse; by race, 39% of white, 41% of Hispanic, and 46% of black participants reported any sexual activity. Overall, 10% of adolescents said they had four or more partners, 3% said they had intercourse before age 13 years, 54% used a condom the last time they had intercourse, and 7% said they were raped.
The rate of STIs in the United States is rising. There has been a sharp increase in the number of combined diagnoses of gonorrhea, syphilis, and chlamydia, with an increase from 1.8 million in 2013 to 2.3 million cases in 2017, according to the Centers for Disease Control and Prevention. During that same time period, gonorrhea increased 67% from 333,004 to 555,608 cases, syphilis (primary and secondary) rose 76% from 17,375 to 30,644 cases, and chlamydia increased 22% to 1.7 million cases.
According to a 2013 CDC infographic shown by Dr. Straub, young people in the United States aged 15-24 years old represent 27% of the total sexually active population but account for 50% of new STI cases each year. Persons in this population account for 70% of gonorrhea cases, 63% of chlamydia cases, 49% of human papillomavirus (HPV) cases, 45% of genital herpes cases, and 20% of syphilis cases.
All sexually active females aged 25 years or younger should be screened for chlamydia and gonorrhea, as well as “at-risk” young men who have sex with men (YMSM), Dr. Straub said. All adolescent males and females aged over 13 years should be offered HIV screening, and HIV screening should be discussed “at least once.” And depending on how at risk each subpopulation is, health care providers should be have that conversation and offer screening multiple times.
Women who have sex with women (WSW) are a diverse population and should be treated based on their individual sexual identities, behaviors, and practices. “Most self-identified WSWs report having sex with men, so therefore adolescent WSWs and females with both male and female sex partners might be at increased risk for STIs, such as syphillis, chlamydia, and HPV as well as HIV, so you may want to adjust your screening accordingly,” she said.
Pregnant women, if at risk, should be screened for HIV, syphilis, hepatitis B, gonorrhea, and chlamydia.
YMSM should have annual screenings for syphilis and HIV, screenings for chlamydia and gonorrhea by infection site; also consider herpes simplex virus serology and anal cytology in these patients, Dr. Straub said. They also should be screened for hepatitis B surface antigen, vaccinated for hepatitis A, hepatitis B and, if using drugs, screened* for hepatitis C virus.
Dr. Straub recommended licensed health care professionals who may treat minor patients review their state’s laws on minors and their legal ability to consent to treatment of STIs without the involvement of their parent or guardian, including disclosure of positive results and in the case of HIV care.
In places where index insured are allowed to find out about any services a beneficiary receives on their insurance, “this is a little problematic, because in some states, this is in direct conflict with the explanation of benefits requirement,” she said. “There are certain ways to get around that, but it’s really important for you to know what the statutes are where you’re practicing and where the breaches of confidentiality [are].”
Expedited partner therapy, or treating one or multiple partners of patients with an STI, is recommended for certain patients and infections, such as male partners of female patients with chlamydia and gonorrhea. While this is recommended less for YMSM because of a higher rate of concurrent infection, “if you have a young person who has partners who are unlikely to have access to care and get treated, it’s recommended you give that treatment to your index patient and to then treat their partners,” Dr. Straub said.
A recent and frequently updated resource on STI treatment can be found at the CDC website.
Dr. Straub reported no relevant conflicts of interest.
*This article was updated 1/11/19.
EXPERT ANALYSIS FROM AAP 18
Antigen profiling may help prevent transfusion complications
BETHESDA, MD. – according to one researcher.
“We strongly feel that you should get an extended red cell type on the first encounter” for patients facing long-term transfusion support, Connie Westhoff, PhD, of the New York Blood Center, said at Sickle Cell in Focus, a conference held by the National Institutes of Health. “This can be a one-time test. It doesn’t have to be repeated.”
She also stressed the importance of ensuring that this information travels with patients, who may be seen at various hospitals. “One of the challenges here is making this part of the patient’s electronic medical record.”
Alloimmunization has been a major concern for chronically transfused patients, so there’s a real advantage to knowing a patient’s extended red cell antigen profile before the patient develops alloantibodies following transfusion, Dr. Westhoff said. Hemolytic transfusion reactions can sometimes destroy patients’ own RBCs in addition to the transfused RBCs. Having the patient’s profile to identify the potential cause of the incompatibility and guide transfusion support in an emergency can be lifesaving.
The implementation of genotyping by DNA-based methods has brought down the cost of this screening, making it no longer a barrier in care.
Dr. Westhoff cited a study she and her colleagues published on a study typing patients who have sickle cell disease (Transfusion. 2015 Jun;55[6 Pt 2]:1388-93). In that paper, they found that DNA-based RBC typing provided improved accuracy and expanded information on RBC antigens, compared with hemagglutination methods. This led to its implementation as the primary method for extended RBC typing for patients with sickle cell disease at the Children’s Hospital of Philadelphia.
About 65%-70% of antibodies drop to levels that are not detectable by routine assays, further demonstrating the need for DNA-based methods. The drugs used to dampen the immune response in many of these patients may also hinder or impact detection of antibodies that remain at levels that continue to cause in vivo hemolysis, Dr. Westhoff said in an interview.
For patients with sickle cell disease in many Western countries, antigen matching for CEK, at a minimum, is routine. The United States is now moving in this direction.
“Modern transfusion practice is moving to knowing what antigens the patient is at risk to become immunized against. ... What antigens does the patient lack and what antibodies could the patient make,” Dr. Westhoff said in an interview. “It’s a major advantage in your transfusion service to expedite work-ups and patient care by having that extended antigen profile.”
Dr. Westhoff reported no relevant financial disclosures.
BETHESDA, MD. – according to one researcher.
“We strongly feel that you should get an extended red cell type on the first encounter” for patients facing long-term transfusion support, Connie Westhoff, PhD, of the New York Blood Center, said at Sickle Cell in Focus, a conference held by the National Institutes of Health. “This can be a one-time test. It doesn’t have to be repeated.”
She also stressed the importance of ensuring that this information travels with patients, who may be seen at various hospitals. “One of the challenges here is making this part of the patient’s electronic medical record.”
Alloimmunization has been a major concern for chronically transfused patients, so there’s a real advantage to knowing a patient’s extended red cell antigen profile before the patient develops alloantibodies following transfusion, Dr. Westhoff said. Hemolytic transfusion reactions can sometimes destroy patients’ own RBCs in addition to the transfused RBCs. Having the patient’s profile to identify the potential cause of the incompatibility and guide transfusion support in an emergency can be lifesaving.
The implementation of genotyping by DNA-based methods has brought down the cost of this screening, making it no longer a barrier in care.
Dr. Westhoff cited a study she and her colleagues published on a study typing patients who have sickle cell disease (Transfusion. 2015 Jun;55[6 Pt 2]:1388-93). In that paper, they found that DNA-based RBC typing provided improved accuracy and expanded information on RBC antigens, compared with hemagglutination methods. This led to its implementation as the primary method for extended RBC typing for patients with sickle cell disease at the Children’s Hospital of Philadelphia.
About 65%-70% of antibodies drop to levels that are not detectable by routine assays, further demonstrating the need for DNA-based methods. The drugs used to dampen the immune response in many of these patients may also hinder or impact detection of antibodies that remain at levels that continue to cause in vivo hemolysis, Dr. Westhoff said in an interview.
For patients with sickle cell disease in many Western countries, antigen matching for CEK, at a minimum, is routine. The United States is now moving in this direction.
“Modern transfusion practice is moving to knowing what antigens the patient is at risk to become immunized against. ... What antigens does the patient lack and what antibodies could the patient make,” Dr. Westhoff said in an interview. “It’s a major advantage in your transfusion service to expedite work-ups and patient care by having that extended antigen profile.”
Dr. Westhoff reported no relevant financial disclosures.
BETHESDA, MD. – according to one researcher.
“We strongly feel that you should get an extended red cell type on the first encounter” for patients facing long-term transfusion support, Connie Westhoff, PhD, of the New York Blood Center, said at Sickle Cell in Focus, a conference held by the National Institutes of Health. “This can be a one-time test. It doesn’t have to be repeated.”
She also stressed the importance of ensuring that this information travels with patients, who may be seen at various hospitals. “One of the challenges here is making this part of the patient’s electronic medical record.”
Alloimmunization has been a major concern for chronically transfused patients, so there’s a real advantage to knowing a patient’s extended red cell antigen profile before the patient develops alloantibodies following transfusion, Dr. Westhoff said. Hemolytic transfusion reactions can sometimes destroy patients’ own RBCs in addition to the transfused RBCs. Having the patient’s profile to identify the potential cause of the incompatibility and guide transfusion support in an emergency can be lifesaving.
The implementation of genotyping by DNA-based methods has brought down the cost of this screening, making it no longer a barrier in care.
Dr. Westhoff cited a study she and her colleagues published on a study typing patients who have sickle cell disease (Transfusion. 2015 Jun;55[6 Pt 2]:1388-93). In that paper, they found that DNA-based RBC typing provided improved accuracy and expanded information on RBC antigens, compared with hemagglutination methods. This led to its implementation as the primary method for extended RBC typing for patients with sickle cell disease at the Children’s Hospital of Philadelphia.
About 65%-70% of antibodies drop to levels that are not detectable by routine assays, further demonstrating the need for DNA-based methods. The drugs used to dampen the immune response in many of these patients may also hinder or impact detection of antibodies that remain at levels that continue to cause in vivo hemolysis, Dr. Westhoff said in an interview.
For patients with sickle cell disease in many Western countries, antigen matching for CEK, at a minimum, is routine. The United States is now moving in this direction.
“Modern transfusion practice is moving to knowing what antigens the patient is at risk to become immunized against. ... What antigens does the patient lack and what antibodies could the patient make,” Dr. Westhoff said in an interview. “It’s a major advantage in your transfusion service to expedite work-ups and patient care by having that extended antigen profile.”
Dr. Westhoff reported no relevant financial disclosures.
REPORTING FROM SICKLE CELL IN FOCUS
DPP-4 drugs for diabetes may protect kidneys too
SAN DIEGO – Dipeptidyl peptidase–4 (DPP-4) inhibitors appear to delay the progression of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM), a new study has found. Researchers also found that all-cause long-term mortality dropped by an astonishing 78% in patients who took the drugs for an average of more than 3 years.
While the reasons for the impressive mortality results are a mystery, “these medications could have a beneficial effect on the kidneys, and it begins to show after 3 years,” said lead author Mariana Garcia-Touza, MD, of the Kansas City (Missouri) Department of Veterans Affairs Medical Center, in an interview. She presented the results at the meeting, sponsored by the American Society of Nephrology.
DPP-4 inhibitor drugs have been available for more than a decade in the United States. The medications, which include sitagliptin (Januvia) and linagliptin (Tradjenta), are used to treat patients with T2DM who are inadequately controlled by first-line treatments.
The drugs have critics. As UpToDate notes, they’re expensive and their effect on glucose levels is “modest.” In addition, UpToDate says, “some of the DPP-4 inhibitors have been associated with an increased risk of heart failure resulting in hospitalization.”
The authors of the new study sought to understand whether the drugs affect kidney function. As Dr. Garcia-Touza noted, metformin, which is processed in part by the kidneys, is considered harmful to certain patients with kidney disease. However, DPP-4 inhibitors are cleared through the liver. In fact, research has suggested the drugs may actually benefit the liver (Med Sci Monit. 2014 Sep 17;20:1662-7).
For the new study, researchers retrospectively analyzed 20,424 patients with T2DM in the VA system who took DPP-4 inhibitors (average age, 68 years) and compared them with a matched group of 52,118 patients with T2DM who didn’t take the drugs, tracking all patients for a mean of over 3 years.
T2DM control improved slightly in the DPP-4 group but remained worse than the non–DPP-4 group. However, “a significant reduction in progression of CKD was seen” in the DPP-4 group, she said.
The number of patients with creatinine levels above 1.5 mg/dL, 3 mg/dL, and 6 mg/dL was reduced by 7%, 41%, and 47%, respectively, in the DPP-4 group, compared with the other group (P less than .01). And the time to end-stage renal disease (creatinine above 6 mg/dL) was delayed by 144 days in the DPP-4 group (P less than .01).
All-cause mortality also fell by 78% in the DPP-4 group (P less than .0001). “Despite having worse glucose control [than the non–DPP-4 group], these patients have better overall mortality,” Dr. Garcia-Touza said.
The drugs may reduce the burden on the kidneys by decreasing inflammation, she said.
Could DPP-4 drugs be beneficial to patients with CKD even if they don’t have T2DM? Dr. Garcia-Touza wasn’t sure. However, she had a theory about why these kidney benefits didn’t show up in previous research. “My impression is that they didn’t go far enough [in time]. That was the main difference.”
Going forward, Dr. Garcia-Touza said her team plans to study the effects of the drugs on retinopathy and diabetic neuropathy.
The study was funded by the Midwest Biomedical Research Foundation and the VA. The study authors reported no relevant disclosures.
SOURCE: Garcia-Tourza M et al. Kidney Week 2018, Abstract TH-OR035.
SAN DIEGO – Dipeptidyl peptidase–4 (DPP-4) inhibitors appear to delay the progression of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM), a new study has found. Researchers also found that all-cause long-term mortality dropped by an astonishing 78% in patients who took the drugs for an average of more than 3 years.
While the reasons for the impressive mortality results are a mystery, “these medications could have a beneficial effect on the kidneys, and it begins to show after 3 years,” said lead author Mariana Garcia-Touza, MD, of the Kansas City (Missouri) Department of Veterans Affairs Medical Center, in an interview. She presented the results at the meeting, sponsored by the American Society of Nephrology.
DPP-4 inhibitor drugs have been available for more than a decade in the United States. The medications, which include sitagliptin (Januvia) and linagliptin (Tradjenta), are used to treat patients with T2DM who are inadequately controlled by first-line treatments.
The drugs have critics. As UpToDate notes, they’re expensive and their effect on glucose levels is “modest.” In addition, UpToDate says, “some of the DPP-4 inhibitors have been associated with an increased risk of heart failure resulting in hospitalization.”
The authors of the new study sought to understand whether the drugs affect kidney function. As Dr. Garcia-Touza noted, metformin, which is processed in part by the kidneys, is considered harmful to certain patients with kidney disease. However, DPP-4 inhibitors are cleared through the liver. In fact, research has suggested the drugs may actually benefit the liver (Med Sci Monit. 2014 Sep 17;20:1662-7).
For the new study, researchers retrospectively analyzed 20,424 patients with T2DM in the VA system who took DPP-4 inhibitors (average age, 68 years) and compared them with a matched group of 52,118 patients with T2DM who didn’t take the drugs, tracking all patients for a mean of over 3 years.
T2DM control improved slightly in the DPP-4 group but remained worse than the non–DPP-4 group. However, “a significant reduction in progression of CKD was seen” in the DPP-4 group, she said.
The number of patients with creatinine levels above 1.5 mg/dL, 3 mg/dL, and 6 mg/dL was reduced by 7%, 41%, and 47%, respectively, in the DPP-4 group, compared with the other group (P less than .01). And the time to end-stage renal disease (creatinine above 6 mg/dL) was delayed by 144 days in the DPP-4 group (P less than .01).
All-cause mortality also fell by 78% in the DPP-4 group (P less than .0001). “Despite having worse glucose control [than the non–DPP-4 group], these patients have better overall mortality,” Dr. Garcia-Touza said.
The drugs may reduce the burden on the kidneys by decreasing inflammation, she said.
Could DPP-4 drugs be beneficial to patients with CKD even if they don’t have T2DM? Dr. Garcia-Touza wasn’t sure. However, she had a theory about why these kidney benefits didn’t show up in previous research. “My impression is that they didn’t go far enough [in time]. That was the main difference.”
Going forward, Dr. Garcia-Touza said her team plans to study the effects of the drugs on retinopathy and diabetic neuropathy.
The study was funded by the Midwest Biomedical Research Foundation and the VA. The study authors reported no relevant disclosures.
SOURCE: Garcia-Tourza M et al. Kidney Week 2018, Abstract TH-OR035.
SAN DIEGO – Dipeptidyl peptidase–4 (DPP-4) inhibitors appear to delay the progression of chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM), a new study has found. Researchers also found that all-cause long-term mortality dropped by an astonishing 78% in patients who took the drugs for an average of more than 3 years.
While the reasons for the impressive mortality results are a mystery, “these medications could have a beneficial effect on the kidneys, and it begins to show after 3 years,” said lead author Mariana Garcia-Touza, MD, of the Kansas City (Missouri) Department of Veterans Affairs Medical Center, in an interview. She presented the results at the meeting, sponsored by the American Society of Nephrology.
DPP-4 inhibitor drugs have been available for more than a decade in the United States. The medications, which include sitagliptin (Januvia) and linagliptin (Tradjenta), are used to treat patients with T2DM who are inadequately controlled by first-line treatments.
The drugs have critics. As UpToDate notes, they’re expensive and their effect on glucose levels is “modest.” In addition, UpToDate says, “some of the DPP-4 inhibitors have been associated with an increased risk of heart failure resulting in hospitalization.”
The authors of the new study sought to understand whether the drugs affect kidney function. As Dr. Garcia-Touza noted, metformin, which is processed in part by the kidneys, is considered harmful to certain patients with kidney disease. However, DPP-4 inhibitors are cleared through the liver. In fact, research has suggested the drugs may actually benefit the liver (Med Sci Monit. 2014 Sep 17;20:1662-7).
For the new study, researchers retrospectively analyzed 20,424 patients with T2DM in the VA system who took DPP-4 inhibitors (average age, 68 years) and compared them with a matched group of 52,118 patients with T2DM who didn’t take the drugs, tracking all patients for a mean of over 3 years.
T2DM control improved slightly in the DPP-4 group but remained worse than the non–DPP-4 group. However, “a significant reduction in progression of CKD was seen” in the DPP-4 group, she said.
The number of patients with creatinine levels above 1.5 mg/dL, 3 mg/dL, and 6 mg/dL was reduced by 7%, 41%, and 47%, respectively, in the DPP-4 group, compared with the other group (P less than .01). And the time to end-stage renal disease (creatinine above 6 mg/dL) was delayed by 144 days in the DPP-4 group (P less than .01).
All-cause mortality also fell by 78% in the DPP-4 group (P less than .0001). “Despite having worse glucose control [than the non–DPP-4 group], these patients have better overall mortality,” Dr. Garcia-Touza said.
The drugs may reduce the burden on the kidneys by decreasing inflammation, she said.
Could DPP-4 drugs be beneficial to patients with CKD even if they don’t have T2DM? Dr. Garcia-Touza wasn’t sure. However, she had a theory about why these kidney benefits didn’t show up in previous research. “My impression is that they didn’t go far enough [in time]. That was the main difference.”
Going forward, Dr. Garcia-Touza said her team plans to study the effects of the drugs on retinopathy and diabetic neuropathy.
The study was funded by the Midwest Biomedical Research Foundation and the VA. The study authors reported no relevant disclosures.
SOURCE: Garcia-Tourza M et al. Kidney Week 2018, Abstract TH-OR035.
REPORTING FROM KIDNEY WEEK 2018
Key clinical point: Dipeptidyl peptidase–4 (DPP-4) inhibitors may delay progression of chronic kidney disease in patients with type 2 diabetes mellitus (T2DM) and may dramatically reduce all-cause mortality.
Major finding: Compared with those who didn’t take the drugs, patients with T2DM who took DPP-4 inhibitors were much less likely to progress to creatinine levels above 1.5 mg/dL, 3 mg/dL, and 6 mg/dL (reduction of 7%, 41%, and 47%, respectively; P less than .01). All-cause mortality in the DPP-4 group fell by 78% (P less than .0001).
Study details: A retrospective study of 20,424 patients with T2DM in the Department of Veterans Affairs system who took DPP-4 inhibitors for mean of more than 3 years and a matched group of 52,118 patients with T2DM who didn’t take the drugs.
Disclosures: The study was funded by the Midwest Biomedical Research Foundation and the VA. The study authors reported no relevant disclosures.
Source: Garcia-Tourza M et al. Kidney Week 2018, Abstract TH-OR035.
Diffuse Pustular Eruption Following Computed Tomography
The Diagnosis: Acute Generalized Exanthematous Pustulosis
Histopathology demonstrated spongiosis with subcorneal pustules and an overlying basket-weave pattern stratum corneum. There was mild papillary dermal edema with scattered dermal neutrophils and rare eosinophils (Figure). The patient's clinical presentation and histopathology were consistent with acute generalized exanthematous pustulosis (AGEP). The inciting agent in this case was the contrast medium iopamidol. The patient was treated with a short course of prednisone, triamcinolone cream, diphenhydramine, and acetaminophen. Within 1 week the pustules and erythema had resolved.
Acute generalized exanthematous pustulosis is an uncommon T cell-mediated cutaneous reaction characterized by widespread progressive erythema with numerous nonfollicular pinpoint pustules. The patient usually is well appearing; however, he/she often will have concurrent fever and facial edema. Mucous membranes rarely are involved. Laboratory results typically are notable only for leukocytosis with neutrophilia.
The pustular eruption typically occurs within 1 to 2 days after exposure to an inciting agent1; however, this latent period can range from 1 hour to nearly 4 weeks in some studies.2 Systemic medications are the cause in approximately 90% of cases, with antibiotics being the most common category. Frequently implicated medications include β-lactams, macrolides, quinolones, sulfonamides, proton pump inhibitors, hydroxychloroquine, terbinafine, nonsteroidal anti-inflammatory drugs, diltiazem, ketoconazole, and fluconazole. Acute generalized exanthematous pustulosis also has been rarely reported following contact with mercury, viral and bacterial infections, and spider bites.3
Iodinated contrast agents have long been known to cause immediate and delayed adverse cutaneous reactions. However, one consensus study indicated that these reactions occur in only 0.05% to 0.10% of patients.4 Although rare, iodinated contrast media (eg, iopamidol, iohexol, ioversol, iodixanol, iomeprol, iobitridol, iopromide) have been reported as a cause of AGEP. A PubMed search of articles indexed for MEDLINE using the terms acute generalized exanthematous pustulosis, contrast, iodine, and iodinated revealed 10 adult cases reported in 6 articles in the English-language literature.1,5-9 The most recent articles focus on methods to identify the causative agent. If the etiology of the reaction is unclear, patch or intradermal testing can help to confirm the causative agent. These tests also can help determine similar agents to which the patient may cross-react.4,5
It can be difficult to differentiate AGEP from other cutaneous drug reactions and other nonfollicular pustular conditions. Drug-induced hypersensitivity syndrome typically presents with facial edema and a morbilliform rash. Although it can present with pustules, the latent period is longer (2-6 weeks), and there frequently are signs of multiorgan involvement including hepatic dysfunction, eosinophilia, atypical lymphocytosis, and lymphadenopathy. Patients with generalized pustular psoriasis often have a history of plaque psoriasis; the pustules are more concentrated in flexural sites; the eruption is gradual in onset; and histologically there tends to be features of psoriasis including parakeratosis, Munro microabscesses, and dilated blood vessels.10 Subcorneal pustular dermatosis also is more concentrated in flexural sites and frequently has an annular or serpiginous configuration. The onset also is gradual, and it follows a more chronic course than AGEP. Exfoliative erythroderma presents with widespread erythema and superficial desquamating scale. It often occurs in association with systemic symptoms and can be the result of a drug reaction or underlying inflammatory dermatosis such as psoriasis, mycosis fungoides, or pityriasis rubra pilaris.
Acute generalized exanthematous pustulosis usually resolves spontaneously within 2 weeks and is associated with a superficial desquamation as it clears. Appropriate treatment includes discontinuing the offending agent; monitoring for systemic involvement; and treating the patient's symptoms with antihistamines, analgesics, topical steroids, and emollients. In more severe or persistent cases, treatment with systemic steroids and tumor necrosis factor α inhibitors has been attempted, though their efficacy remains unclear. We report a case of iopamidol-induced AGEP that highlights the importance of eliciting a history of contrast exposure from a patient with suspected AGEP.
- Hammerbeck AA, Daniels NH, Callen JP. Ioversol-induced acute generalized exanthematous pustulosis. Arch Dermatol. 2009;145:683-687.
- Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:1-8.
- Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2016;73:843-848.
- Rosado Ingelmo A, Doña Diaz I, Cabañas Moreno R, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. J Investig Allergol Clin Immunol. 2016;26:144-155.
- Grandvuillemin A, Ripert C, Sgro C, et al. Iodinated contrast media-induced acute generalized exanthematous pustulosis confirmed by delayed skin tests. J Allergy Clin Immunol Pract. 2014;2:805-806.
- Bavbek S, Sözener ZÇ, Aydin Ö, et al. First case report of acute generalized exanthematous pustulosis due to intravenous iopromide. J Investig Allergol Clin Immunol. 2014;24:66-67.
- Kim SJ, Lee T, Lee YS, et al. Acute generalized exanthematous pustulosis caused by radiocontrast media. Ann Allergy Asthma Immunol. 2010;105:492-493.
- Peterson A, Katzberg RW, Fung MA, et al. Acute generalized exanthematous pustulosis as a delayed dermatotoxic reaction to IV-administered nonionic contrast media. Am J Roentgenol. 2006;187:198-201.
- Atasoy M, Erdem T, Sari RA. A case of acute generalized exanthematous pustulosis (AGEP) possibly induced by iohexol. J Dermatol. 2003;30:723-726.
- Halevy S, Kardaun S, Davidovici B, et al; EuroSCAR and RegiSCAR Study Group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol. 2010:163:1245-1252.
The Diagnosis: Acute Generalized Exanthematous Pustulosis
Histopathology demonstrated spongiosis with subcorneal pustules and an overlying basket-weave pattern stratum corneum. There was mild papillary dermal edema with scattered dermal neutrophils and rare eosinophils (Figure). The patient's clinical presentation and histopathology were consistent with acute generalized exanthematous pustulosis (AGEP). The inciting agent in this case was the contrast medium iopamidol. The patient was treated with a short course of prednisone, triamcinolone cream, diphenhydramine, and acetaminophen. Within 1 week the pustules and erythema had resolved.
Acute generalized exanthematous pustulosis is an uncommon T cell-mediated cutaneous reaction characterized by widespread progressive erythema with numerous nonfollicular pinpoint pustules. The patient usually is well appearing; however, he/she often will have concurrent fever and facial edema. Mucous membranes rarely are involved. Laboratory results typically are notable only for leukocytosis with neutrophilia.
The pustular eruption typically occurs within 1 to 2 days after exposure to an inciting agent1; however, this latent period can range from 1 hour to nearly 4 weeks in some studies.2 Systemic medications are the cause in approximately 90% of cases, with antibiotics being the most common category. Frequently implicated medications include β-lactams, macrolides, quinolones, sulfonamides, proton pump inhibitors, hydroxychloroquine, terbinafine, nonsteroidal anti-inflammatory drugs, diltiazem, ketoconazole, and fluconazole. Acute generalized exanthematous pustulosis also has been rarely reported following contact with mercury, viral and bacterial infections, and spider bites.3
Iodinated contrast agents have long been known to cause immediate and delayed adverse cutaneous reactions. However, one consensus study indicated that these reactions occur in only 0.05% to 0.10% of patients.4 Although rare, iodinated contrast media (eg, iopamidol, iohexol, ioversol, iodixanol, iomeprol, iobitridol, iopromide) have been reported as a cause of AGEP. A PubMed search of articles indexed for MEDLINE using the terms acute generalized exanthematous pustulosis, contrast, iodine, and iodinated revealed 10 adult cases reported in 6 articles in the English-language literature.1,5-9 The most recent articles focus on methods to identify the causative agent. If the etiology of the reaction is unclear, patch or intradermal testing can help to confirm the causative agent. These tests also can help determine similar agents to which the patient may cross-react.4,5
It can be difficult to differentiate AGEP from other cutaneous drug reactions and other nonfollicular pustular conditions. Drug-induced hypersensitivity syndrome typically presents with facial edema and a morbilliform rash. Although it can present with pustules, the latent period is longer (2-6 weeks), and there frequently are signs of multiorgan involvement including hepatic dysfunction, eosinophilia, atypical lymphocytosis, and lymphadenopathy. Patients with generalized pustular psoriasis often have a history of plaque psoriasis; the pustules are more concentrated in flexural sites; the eruption is gradual in onset; and histologically there tends to be features of psoriasis including parakeratosis, Munro microabscesses, and dilated blood vessels.10 Subcorneal pustular dermatosis also is more concentrated in flexural sites and frequently has an annular or serpiginous configuration. The onset also is gradual, and it follows a more chronic course than AGEP. Exfoliative erythroderma presents with widespread erythema and superficial desquamating scale. It often occurs in association with systemic symptoms and can be the result of a drug reaction or underlying inflammatory dermatosis such as psoriasis, mycosis fungoides, or pityriasis rubra pilaris.
Acute generalized exanthematous pustulosis usually resolves spontaneously within 2 weeks and is associated with a superficial desquamation as it clears. Appropriate treatment includes discontinuing the offending agent; monitoring for systemic involvement; and treating the patient's symptoms with antihistamines, analgesics, topical steroids, and emollients. In more severe or persistent cases, treatment with systemic steroids and tumor necrosis factor α inhibitors has been attempted, though their efficacy remains unclear. We report a case of iopamidol-induced AGEP that highlights the importance of eliciting a history of contrast exposure from a patient with suspected AGEP.
The Diagnosis: Acute Generalized Exanthematous Pustulosis
Histopathology demonstrated spongiosis with subcorneal pustules and an overlying basket-weave pattern stratum corneum. There was mild papillary dermal edema with scattered dermal neutrophils and rare eosinophils (Figure). The patient's clinical presentation and histopathology were consistent with acute generalized exanthematous pustulosis (AGEP). The inciting agent in this case was the contrast medium iopamidol. The patient was treated with a short course of prednisone, triamcinolone cream, diphenhydramine, and acetaminophen. Within 1 week the pustules and erythema had resolved.
Acute generalized exanthematous pustulosis is an uncommon T cell-mediated cutaneous reaction characterized by widespread progressive erythema with numerous nonfollicular pinpoint pustules. The patient usually is well appearing; however, he/she often will have concurrent fever and facial edema. Mucous membranes rarely are involved. Laboratory results typically are notable only for leukocytosis with neutrophilia.
The pustular eruption typically occurs within 1 to 2 days after exposure to an inciting agent1; however, this latent period can range from 1 hour to nearly 4 weeks in some studies.2 Systemic medications are the cause in approximately 90% of cases, with antibiotics being the most common category. Frequently implicated medications include β-lactams, macrolides, quinolones, sulfonamides, proton pump inhibitors, hydroxychloroquine, terbinafine, nonsteroidal anti-inflammatory drugs, diltiazem, ketoconazole, and fluconazole. Acute generalized exanthematous pustulosis also has been rarely reported following contact with mercury, viral and bacterial infections, and spider bites.3
Iodinated contrast agents have long been known to cause immediate and delayed adverse cutaneous reactions. However, one consensus study indicated that these reactions occur in only 0.05% to 0.10% of patients.4 Although rare, iodinated contrast media (eg, iopamidol, iohexol, ioversol, iodixanol, iomeprol, iobitridol, iopromide) have been reported as a cause of AGEP. A PubMed search of articles indexed for MEDLINE using the terms acute generalized exanthematous pustulosis, contrast, iodine, and iodinated revealed 10 adult cases reported in 6 articles in the English-language literature.1,5-9 The most recent articles focus on methods to identify the causative agent. If the etiology of the reaction is unclear, patch or intradermal testing can help to confirm the causative agent. These tests also can help determine similar agents to which the patient may cross-react.4,5
It can be difficult to differentiate AGEP from other cutaneous drug reactions and other nonfollicular pustular conditions. Drug-induced hypersensitivity syndrome typically presents with facial edema and a morbilliform rash. Although it can present with pustules, the latent period is longer (2-6 weeks), and there frequently are signs of multiorgan involvement including hepatic dysfunction, eosinophilia, atypical lymphocytosis, and lymphadenopathy. Patients with generalized pustular psoriasis often have a history of plaque psoriasis; the pustules are more concentrated in flexural sites; the eruption is gradual in onset; and histologically there tends to be features of psoriasis including parakeratosis, Munro microabscesses, and dilated blood vessels.10 Subcorneal pustular dermatosis also is more concentrated in flexural sites and frequently has an annular or serpiginous configuration. The onset also is gradual, and it follows a more chronic course than AGEP. Exfoliative erythroderma presents with widespread erythema and superficial desquamating scale. It often occurs in association with systemic symptoms and can be the result of a drug reaction or underlying inflammatory dermatosis such as psoriasis, mycosis fungoides, or pityriasis rubra pilaris.
Acute generalized exanthematous pustulosis usually resolves spontaneously within 2 weeks and is associated with a superficial desquamation as it clears. Appropriate treatment includes discontinuing the offending agent; monitoring for systemic involvement; and treating the patient's symptoms with antihistamines, analgesics, topical steroids, and emollients. In more severe or persistent cases, treatment with systemic steroids and tumor necrosis factor α inhibitors has been attempted, though their efficacy remains unclear. We report a case of iopamidol-induced AGEP that highlights the importance of eliciting a history of contrast exposure from a patient with suspected AGEP.
- Hammerbeck AA, Daniels NH, Callen JP. Ioversol-induced acute generalized exanthematous pustulosis. Arch Dermatol. 2009;145:683-687.
- Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:1-8.
- Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2016;73:843-848.
- Rosado Ingelmo A, Doña Diaz I, Cabañas Moreno R, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. J Investig Allergol Clin Immunol. 2016;26:144-155.
- Grandvuillemin A, Ripert C, Sgro C, et al. Iodinated contrast media-induced acute generalized exanthematous pustulosis confirmed by delayed skin tests. J Allergy Clin Immunol Pract. 2014;2:805-806.
- Bavbek S, Sözener ZÇ, Aydin Ö, et al. First case report of acute generalized exanthematous pustulosis due to intravenous iopromide. J Investig Allergol Clin Immunol. 2014;24:66-67.
- Kim SJ, Lee T, Lee YS, et al. Acute generalized exanthematous pustulosis caused by radiocontrast media. Ann Allergy Asthma Immunol. 2010;105:492-493.
- Peterson A, Katzberg RW, Fung MA, et al. Acute generalized exanthematous pustulosis as a delayed dermatotoxic reaction to IV-administered nonionic contrast media. Am J Roentgenol. 2006;187:198-201.
- Atasoy M, Erdem T, Sari RA. A case of acute generalized exanthematous pustulosis (AGEP) possibly induced by iohexol. J Dermatol. 2003;30:723-726.
- Halevy S, Kardaun S, Davidovici B, et al; EuroSCAR and RegiSCAR Study Group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol. 2010:163:1245-1252.
- Hammerbeck AA, Daniels NH, Callen JP. Ioversol-induced acute generalized exanthematous pustulosis. Arch Dermatol. 2009;145:683-687.
- Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:1-8.
- Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2016;73:843-848.
- Rosado Ingelmo A, Doña Diaz I, Cabañas Moreno R, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to contrast media. J Investig Allergol Clin Immunol. 2016;26:144-155.
- Grandvuillemin A, Ripert C, Sgro C, et al. Iodinated contrast media-induced acute generalized exanthematous pustulosis confirmed by delayed skin tests. J Allergy Clin Immunol Pract. 2014;2:805-806.
- Bavbek S, Sözener ZÇ, Aydin Ö, et al. First case report of acute generalized exanthematous pustulosis due to intravenous iopromide. J Investig Allergol Clin Immunol. 2014;24:66-67.
- Kim SJ, Lee T, Lee YS, et al. Acute generalized exanthematous pustulosis caused by radiocontrast media. Ann Allergy Asthma Immunol. 2010;105:492-493.
- Peterson A, Katzberg RW, Fung MA, et al. Acute generalized exanthematous pustulosis as a delayed dermatotoxic reaction to IV-administered nonionic contrast media. Am J Roentgenol. 2006;187:198-201.
- Atasoy M, Erdem T, Sari RA. A case of acute generalized exanthematous pustulosis (AGEP) possibly induced by iohexol. J Dermatol. 2003;30:723-726.
- Halevy S, Kardaun S, Davidovici B, et al; EuroSCAR and RegiSCAR Study Group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol. 2010:163:1245-1252.
A 31-year-old man presented with a rapidly progressive, burning rash of 1 day's duration, along with malaise, nausea, and dizziness. At the time of presentation, he was hemodynamically stable and afebrile. Laboratory analysis revealed mild leukocytosis with neutrophilia. A complete metabolic panel was within normal limits. He had no chronic medical conditions and was taking no medications or supplements. One day prior to onset of the rash, he underwent contrast-enhanced (iopamidol) computed tomography of the abdomen. Physical examination revealed large edematous plaques on the face, neck, and trunk (top) that were studded with numerous pinpoint pustules (bottom). He also had subtle facial edema. There was relative sparing of the flexural sites and no involvement of the palms, soles, or mucous membranes. A shave biopsy was obtained from a pustular area on the neck.
Google Search Results for Diet and Psoriasis: Advice Patients Get on the Internet
Report details financial burden of blood cancers
with costs for acute leukemia almost tripling that amount, according to a new report from the Leukemia & Lymphoma Society (LLS).
Total allowed cost – the average amount paid by the insurer and patient combined – for acute leukemia was more than $463,000 for the 12 months after initial diagnosis. Averages for the other four cancers included in the analysis came in at $214,000 for multiple myeloma, $134,000 for bone marrow disorders, $131,000 for lymphoma, and $89,000 for chronic leukemia, the LLS said.
The cost figures are drawn from claims data for 2,332 patients diagnosed in 2014.
Differences in out-of-pocket (OOP) costs were smaller, with the average for all patients at almost $3,900 in the year after diagnosis and acute leukemia coming in the highest at $5,100. Over time, however, OOP costs for multiple myeloma patients became the highest, totaling $9,100 for the 3 years after diagnosis, compared with $8,800 for acute leukemia and an average of less than $7,800 for the other blood cancers, the LLS said in the report, which was prepared by the actuarial firm Milliman.
OOP costs also varied by the type of plan. Patients in high-deductible plans averaged nearly $5,400 for the first year after diagnosis, compared with $3,300 for those with traditional insurance, the LLS noted. For acute leukemia, the OOP costs of high-deductible plans were more than twice as high as those of traditional plans.
The study was based on data for adults aged 18-64 years from the Truven Health MarketScan commercial claims databases for the years from 2013 to 2016. The LLS received support for the study from Pfizer, Genentech, and Amgen.
with costs for acute leukemia almost tripling that amount, according to a new report from the Leukemia & Lymphoma Society (LLS).
Total allowed cost – the average amount paid by the insurer and patient combined – for acute leukemia was more than $463,000 for the 12 months after initial diagnosis. Averages for the other four cancers included in the analysis came in at $214,000 for multiple myeloma, $134,000 for bone marrow disorders, $131,000 for lymphoma, and $89,000 for chronic leukemia, the LLS said.
The cost figures are drawn from claims data for 2,332 patients diagnosed in 2014.
Differences in out-of-pocket (OOP) costs were smaller, with the average for all patients at almost $3,900 in the year after diagnosis and acute leukemia coming in the highest at $5,100. Over time, however, OOP costs for multiple myeloma patients became the highest, totaling $9,100 for the 3 years after diagnosis, compared with $8,800 for acute leukemia and an average of less than $7,800 for the other blood cancers, the LLS said in the report, which was prepared by the actuarial firm Milliman.
OOP costs also varied by the type of plan. Patients in high-deductible plans averaged nearly $5,400 for the first year after diagnosis, compared with $3,300 for those with traditional insurance, the LLS noted. For acute leukemia, the OOP costs of high-deductible plans were more than twice as high as those of traditional plans.
The study was based on data for adults aged 18-64 years from the Truven Health MarketScan commercial claims databases for the years from 2013 to 2016. The LLS received support for the study from Pfizer, Genentech, and Amgen.
with costs for acute leukemia almost tripling that amount, according to a new report from the Leukemia & Lymphoma Society (LLS).
Total allowed cost – the average amount paid by the insurer and patient combined – for acute leukemia was more than $463,000 for the 12 months after initial diagnosis. Averages for the other four cancers included in the analysis came in at $214,000 for multiple myeloma, $134,000 for bone marrow disorders, $131,000 for lymphoma, and $89,000 for chronic leukemia, the LLS said.
The cost figures are drawn from claims data for 2,332 patients diagnosed in 2014.
Differences in out-of-pocket (OOP) costs were smaller, with the average for all patients at almost $3,900 in the year after diagnosis and acute leukemia coming in the highest at $5,100. Over time, however, OOP costs for multiple myeloma patients became the highest, totaling $9,100 for the 3 years after diagnosis, compared with $8,800 for acute leukemia and an average of less than $7,800 for the other blood cancers, the LLS said in the report, which was prepared by the actuarial firm Milliman.
OOP costs also varied by the type of plan. Patients in high-deductible plans averaged nearly $5,400 for the first year after diagnosis, compared with $3,300 for those with traditional insurance, the LLS noted. For acute leukemia, the OOP costs of high-deductible plans were more than twice as high as those of traditional plans.
The study was based on data for adults aged 18-64 years from the Truven Health MarketScan commercial claims databases for the years from 2013 to 2016. The LLS received support for the study from Pfizer, Genentech, and Amgen.
Surgical repair of hip fractures in nursing home patients
Clinical question: Does surgical repair of hip fractures in nursing home residents with advanced dementia reduce adverse outcomes?
Background: Hip fractures are common in the advanced dementia nursing home population. The benefit of surgical repair is unclear in this population given significant baseline functional disability and limited life expectancy.
Study design: Retrospective cohort study.
Setting: Medicare claims data set.
Synopsis: Among 3,083 nursing home residents with advanced dementia and hip fracture, nearly 85% underwent surgical repair. The 30-day mortality rate in the nonsurgical group was 30.6%, compared with 11.5% in the surgical group. In an adjusted model, the surgical group had decreased risk of death, compared with the nonsurgical group (hazard ratio, 0.88; 95% confidence interval, 0.79-0.98). In additional adjusted models, surgical patients also had decreased risk of pressure ulcers (HR 0.64; 95% CI, 0.47-0.86) and less pain (HR, 0.78; 95% CI, 0.61-0.99). Limitations included the observational nature of the study. Although the models were adjusted, unmeasured confounding may have contributed to the findings.
Bottom line: Surgical repair of hip fractures in nursing home patients with advanced dementia reduces post-fracture mortality, pain, and pressure ulcer risk.
Citation: Berry SD et al. Association of clinical outcomes with surgical repair of hip fracture vs. nonsurgical management in nursing home residents with advanced dementia. JAMA Intern Med. 2018;178(6):774-80.
Dr. Abramowicz is an assistant professor in the division of hospital medicine, University of Colorado, Denver.
Clinical question: Does surgical repair of hip fractures in nursing home residents with advanced dementia reduce adverse outcomes?
Background: Hip fractures are common in the advanced dementia nursing home population. The benefit of surgical repair is unclear in this population given significant baseline functional disability and limited life expectancy.
Study design: Retrospective cohort study.
Setting: Medicare claims data set.
Synopsis: Among 3,083 nursing home residents with advanced dementia and hip fracture, nearly 85% underwent surgical repair. The 30-day mortality rate in the nonsurgical group was 30.6%, compared with 11.5% in the surgical group. In an adjusted model, the surgical group had decreased risk of death, compared with the nonsurgical group (hazard ratio, 0.88; 95% confidence interval, 0.79-0.98). In additional adjusted models, surgical patients also had decreased risk of pressure ulcers (HR 0.64; 95% CI, 0.47-0.86) and less pain (HR, 0.78; 95% CI, 0.61-0.99). Limitations included the observational nature of the study. Although the models were adjusted, unmeasured confounding may have contributed to the findings.
Bottom line: Surgical repair of hip fractures in nursing home patients with advanced dementia reduces post-fracture mortality, pain, and pressure ulcer risk.
Citation: Berry SD et al. Association of clinical outcomes with surgical repair of hip fracture vs. nonsurgical management in nursing home residents with advanced dementia. JAMA Intern Med. 2018;178(6):774-80.
Dr. Abramowicz is an assistant professor in the division of hospital medicine, University of Colorado, Denver.
Clinical question: Does surgical repair of hip fractures in nursing home residents with advanced dementia reduce adverse outcomes?
Background: Hip fractures are common in the advanced dementia nursing home population. The benefit of surgical repair is unclear in this population given significant baseline functional disability and limited life expectancy.
Study design: Retrospective cohort study.
Setting: Medicare claims data set.
Synopsis: Among 3,083 nursing home residents with advanced dementia and hip fracture, nearly 85% underwent surgical repair. The 30-day mortality rate in the nonsurgical group was 30.6%, compared with 11.5% in the surgical group. In an adjusted model, the surgical group had decreased risk of death, compared with the nonsurgical group (hazard ratio, 0.88; 95% confidence interval, 0.79-0.98). In additional adjusted models, surgical patients also had decreased risk of pressure ulcers (HR 0.64; 95% CI, 0.47-0.86) and less pain (HR, 0.78; 95% CI, 0.61-0.99). Limitations included the observational nature of the study. Although the models were adjusted, unmeasured confounding may have contributed to the findings.
Bottom line: Surgical repair of hip fractures in nursing home patients with advanced dementia reduces post-fracture mortality, pain, and pressure ulcer risk.
Citation: Berry SD et al. Association of clinical outcomes with surgical repair of hip fracture vs. nonsurgical management in nursing home residents with advanced dementia. JAMA Intern Med. 2018;178(6):774-80.
Dr. Abramowicz is an assistant professor in the division of hospital medicine, University of Colorado, Denver.
Hypertension and CVD risk for young adults
The medical community is struggling to reach a vaccine for Hepatitis C virus, many teens don’t know that e-cigarettes contain nicotine, and there’s a duel in SLE classification criteria,
Amazon Alexa
Apple Podcasts
Spotify
The medical community is struggling to reach a vaccine for Hepatitis C virus, many teens don’t know that e-cigarettes contain nicotine, and there’s a duel in SLE classification criteria,
Amazon Alexa
Apple Podcasts
Spotify
The medical community is struggling to reach a vaccine for Hepatitis C virus, many teens don’t know that e-cigarettes contain nicotine, and there’s a duel in SLE classification criteria,
Amazon Alexa
Apple Podcasts
Spotify
Gastric Banding vs Metformin
Gastric banding was just as successful as metformin alone in stabilizing prediabetes or new-onset type 2 diabetes in the Beta Cell Restoration through Fat Mitigation study (BetaFat), an NIH-supported study.
The study is part of the Restoring Insulin Secretion (RISE) study, a set of 3 clinical trials designed to find ways to reverse or slow the loss of insulin production and release in people at risk for type 2 diabetes.
In this study, 44 patients were randomly assigned to have a gastric banding procedure, and 44 were taking metformin. After 2 years, people in the gastric banding group had lost an average of 23 lb , vs 4 lb in the metformin group. Insulin sensitivity improved similarly in both groups, as did function of insulin-producing cells. Both groups showed small improvements in blood glucose levels.
Gastric banding was just as successful as metformin alone in stabilizing prediabetes or new-onset type 2 diabetes in the Beta Cell Restoration through Fat Mitigation study (BetaFat), an NIH-supported study.
The study is part of the Restoring Insulin Secretion (RISE) study, a set of 3 clinical trials designed to find ways to reverse or slow the loss of insulin production and release in people at risk for type 2 diabetes.
In this study, 44 patients were randomly assigned to have a gastric banding procedure, and 44 were taking metformin. After 2 years, people in the gastric banding group had lost an average of 23 lb , vs 4 lb in the metformin group. Insulin sensitivity improved similarly in both groups, as did function of insulin-producing cells. Both groups showed small improvements in blood glucose levels.
Gastric banding was just as successful as metformin alone in stabilizing prediabetes or new-onset type 2 diabetes in the Beta Cell Restoration through Fat Mitigation study (BetaFat), an NIH-supported study.
The study is part of the Restoring Insulin Secretion (RISE) study, a set of 3 clinical trials designed to find ways to reverse or slow the loss of insulin production and release in people at risk for type 2 diabetes.
In this study, 44 patients were randomly assigned to have a gastric banding procedure, and 44 were taking metformin. After 2 years, people in the gastric banding group had lost an average of 23 lb , vs 4 lb in the metformin group. Insulin sensitivity improved similarly in both groups, as did function of insulin-producing cells. Both groups showed small improvements in blood glucose levels.